City of Hope, Duarte
University of California, Los Angeles (UCLA) - Medical Center, Los Angeles
University of California, San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center, San Francisco

U tijeku regrutacijaFaza 1

Od 18 godina i više · Oba spola · Ažurirano 22. ruj 2026. · NCT07226843

Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma

City of Hope Medical Center, Duarte
City of Hope Orange County Lennar Foundation Cancer Center, Irvine

U tijeku regrutacijaFaza 2

Od 18 godina i više · Oba spola · Ažurirano 22. ruj 2026. · NCT06453044

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

City of Hope, Duarte

U tijeku regrutacijaFaza 1

Od 18 godina i više · Oba spola · Ažurirano 22. ruj 2026. · NCT07101328

A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

Research Site, Clovis
Research Site, Los Alamitos
Research Site, San Diego
i još 1

U tijeku regrutacijaFaza 3

Od 18 do 130 godina · Oba spola · Ažurirano 21. ruj 2026. · NCT06549595

NEO100 and High-Grade Meningioma

University of Southern California, Los Angeles
Sutter Health Research Institute, San Francisco
Saint John Cancer Institute, Santa Monica

U tijeku regrutacijaFaza 2

Od 12 godina i više · Oba spola · Ažurirano 15. ruj 2026. · NCT05023018

Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL

Research Site, Duarte

U tijeku regrutacijaFaza 2

Od 18 godina i više · Oba spola · Ažurirano 11. ruj 2026. · NCT06526793

A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

David Geffen School of Medicine at UCLA, Los Angeles

U tijeku regrutacijaFaza 3

Od 18 godina i više · Oba spola · Ažurirano 11. ruj 2026. · NCT06091254

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

City of Hope Comprehensive Cancer Center, Duarte
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
UC San Diego Moores Cancer Center, La Jolla
i još 2

U tijeku regrutacijaFaza 1

Od 18 godina i više · Oba spola · Ažurirano 2. ruj 2026. · NCT06860594

A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234

Research Site, Rialto

U tijeku regrutacijaFaza 1Zdravi dobrovoljci dobrodošli

Od 18 do 85 godina · Oba spola · Ažurirano 1. ruj 2026. · NCT07546760

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

University of California San Diego, La Jolla
University of California, Los Angeles, Los Angeles
Hoag Memorial Hospital Presbyterian, Newport Beach
i još 2

U tijeku regrutacijaFaza 3

Od 18 godina i više · Oba spola · Ažurirano 28. kol 2026. · NCT05303519

A Study of ARC-02 in B-cell NHL

Start Cala, Los Angeles

U tijeku regrutacijaFaza 1

Od 18 godina i više · Oba spola · Ažurirano 26. kol 2026. · NCT07691606

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

University of California-Irvine Medical Center, Irvine
Cedars-Sinai Medical Center, Los Angeles
University of California, Los Angeles (UCLA) Medical Center, Los Angeles
i još 1

U tijeku regrutacijaFaza 1/2

Od 18 godina i više · Oba spola · Ažurirano 25. kol 2026. · NCT05826535

A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma

David Geffen School of Medicine at UCLA, Los Angeles

U tijeku regrutacijaFaza 3

Od 18 godina i više · Oba spola · Ažurirano 14. kol 2026. · NCT06149286

AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas

Stanford University, Palo Alto

U tijeku regrutacijaFaza 1

Od 18 godina i više · Oba spola · Ažurirano 12. kol 2026. · NCT06340737

Interventions in Mathematics and Cognitive Skills

Stanford Cognitive and Systems Neuroscience Laboratory, Palo Alto

U tijeku regrutacijaZdravi dobrovoljci dobrodošli

Od 6 do 12 godina · Oba spola · Ažurirano 11. kol 2026. · NCT05201534

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

City of Hope, Duarte
Valkyrie Clinical Trials, Los Angeles

U tijeku regrutacijaFaza 1/2

Od 13 do 90 godina · Oba spola · Ažurirano 6. kol 2026. · NCT06533579

STimulation to Activate RespIration

University of California San Diego, La Jolla

U tijeku regrutacija

Od 18 godina i više · Oba spola · Ažurirano 6. kol 2026. · NCT06832306

A Study of APG-3288 in Relapsed/Refractory Blood Cancers

START Los Angele, Los Angeles

U tijeku regrutacijaFaza 1

Od 18 godina i više · Oba spola · Ažurirano 30. srp 2026. · NCT07424833

This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma

City of Hope, Duarte

U tijeku regrutacijaFaza 1

Od 18 godina i više · Oba spola · Ažurirano 24. srp 2026. · NCT07121946

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

City of Hope, Duarte
University of California, San Francisco, San Francisco

U tijeku regrutacijaFaza 1

Od 18 godina i više · Oba spola · Ažurirano 2. srp 2026. · NCT05131022

Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma

University of California Davis Comprehensive Cancer Center, Sacramento

U tijeku regrutacijaFaza 2

Od 18 godina i više · Oba spola · Ažurirano 29. lip 2026. · NCT04587687

Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma

City of Hope Medical Center, Duarte

U tijeku regrutacijaFaza 1

Od 18 godina i više · Oba spola · Ažurirano 29. lip 2026. · NCT06815029

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

University of California, San Francisco, San Francisco

U tijeku regrutacijaFaza 1

Od 18 godina i više · Oba spola · Ažurirano 22. lip 2026. · NCT04545762

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

City of Hope Comprehensive Cancer Center, Duarte
UCSF Helen Diller Medical Center at Parnassus Heights, San Francisco

U tijeku regrutacijaFaza 3

Od 18 godina i više · Oba spola · Ažurirano 20. svi 2026. · NCT06911502

Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

City of Hope Medical Center, Duarte

U tijeku regrutacijaFaza 1

Od 18 godina i više · Oba spola · Ažurirano 20. tra 2026. · NCT06859008

The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies

City of Hope, Duarte
Los Angeles Cancer Network, Los Angeles
UCLA Medical Center of Hematology/Oncology, Los Angeles
i još 1

U tijeku regrutacijaFaza 1/2

Od 12 do 95 godina · Oba spola · Ažurirano 15. tra 2026. · NCT04329728

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

City of Hope, Duarte

U tijeku regrutacijaFaza 1

Od 18 godina i više · Oba spola · Ažurirano 20. ožu 2026. · NCT04830137

Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy

Stanford, Stanford

U tijeku regrutacijaFaza 2

Od 18 godina i više · Oba spola · Ažurirano 13. ožu 2026. · NCT06510361

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

UC Irvine Health, Orange

U tijeku regrutacijaFaza 1

Od 18 godina i više · Oba spola · Ažurirano 10. pro 2025. · NCT05602363

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Massive Bio SYNERGY-AI site, Duarte
Massive Bio SYNERGY-AI site, Irvine
Massive Bio SYNERGY-AI site, La Jolla
i još 3

U tijeku regrutacijaOpažajna studija

Sve dobne skupine · Oba spola · Ažurirano 28. lis 2025. · NCT03452774

Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy

Stanford Cancer Center, Palo Alto

U tijeku regrutacijaOpažajna studija

Od 18 godina i više · Oba spola · Ažurirano 22. kol 2024. · NCT05255354

Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.